COVID-19
COVID-19 VACCINE. A 53-PAGE DOCUMENT WAS RELEASED TODAY THAT ANALYZES PFIZER'S DATA ON THE
COMPANY'S PHASE 3 COVID-19
VACCINE CLINICAL TRIAL.
THE FINDINGS WERE MADE PUBLIC
TODAY. 12NEWS INVESTIGATOR
LAUREN HENSLEY IS LIVE WITH THE
BIG HEADLINES.
JORDAN-- A LOT IS RIDING ON
THIS F-D-A BRIEFING DOCUMENT.
THURSDAY -- THE F-D-A ADVISORY
COMMITTEE WILL MEET TO DISCUSS
ITS FINDINGS. THE
INFORMATION WILL BE USED TO
APPROVE OR DENY EMERGENCY USE
AUTHORIZATION FOR PFIZER'S
COVID-19 VACCINE.
THE PFIZER VACCINE CALLS FOR
TWO DOSES, THREE WEEKS APART.
RESULTS FROM ITS PHASE 3
CLINICAL TRIALS SHOWS THAT WITH
THE TWO DOSES THE VACCINES IS
ABOUT 95 PERCENT EFFECTIVE IN
PREVENTING SYMPTOMATIC COVID-19.
THIS INCLUDES PEOPLE WITH
UNDERLYING HEALTH CONDITIONS
LIKE -- OBESITY OR DIABETES.
AND AFTER JUST ONE DOSE--- THE
FINDINGS SHOW-- IT APPEARS TO BE
50 PERCENT EFFECTIVE. AN
IMPORTANT NOTE HERE-- THIS WAS
NOT A TRIAL TO UNDERSTAND THE
RESPONSE OF A SINGLE-DOSE. THIS
WAS AN OBSERVATION MADE WHILE
PARTICIPANTS WERE WAITING TO
RECEIVE THEIR SECOND DOSE OF THE
VACCINE. THE MOST COMMON
SIDE EFFECT? FATIGUE, FEVER,
HEADACHES, MUSCLE, AND JOINT
PAIN.
A TOTAL OF SIX PARTICIPANTS
DIED DURING THE TRIALS---2 WHO
RECEIVED THE VACCINE... AND 4
WHO WERE GIVEN A PLACEBO. NONE
OF THOSE DEATHS WAS LINKED TO
THE VACCINE. COMING UP
TONIGHT AT 6... WE ARE DIVING
DEEPER INTO THE DEMOGRAPHICS....
AND ANSWERING SOME OF YOUR TOP
VACCINE QUESTIONS. LAUREN
HENSLEY 12NEWS.